Journal of Cystic Fibrosis
Volume 5, Issue 4 , Pages 205-213 , December 2006

Inhalation solutions – which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers

  • Wolfgang Kamin

      Affiliations

    • Kinderklinik und Kinderpoliklinik der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55101 Mainz, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 6131 17 2602; fax: +49 6131 17 5597.
    • ,
  • Astrid Schwabe

      Affiliations

    • Apotheke der Unikliniken Mainz, Langenbeckstr. 1, D-55131 Mainz, Germany
    • Tel.: +49 6131 17 4224; fax: +49 6131 17 5564.
    • ,
  • Irene Krämer

      Affiliations

    • Apotheke der Unikliniken Mainz, Langenbeckstr. 1, D-55131 Mainz, Germany
    • Tel.: +49 6131 17 7209; fax: +49 6131 17 5525.

Received 20 October 2005 ,Revised 21 December 2005 ,Accepted 16 March 2006.

References 

  1. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, et al. For the society task force on the use of nebulizers. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J. 2001;18:228–242
  2. American Society of Health System Pharmacists Inc. . In: International pharmaceutical abstracts. New York: Silver Platter International; 2003;p. I31
  3. In:  Hutchinson TA,  Shahan DR editor. DRUGDEX® system. Greenwood Village, CO: Micromedex; 2004;p. 121
  4. American Society of Health-System Pharmacists Inc. . AHFS drug information 2003. Bethesda: ASHP; 2003;
  5. Trissel LA. Handbook on injectable drugs. 12th Ed.. ASHP; 2003;
  6. Gooch MD. Stability of albuterol and tobramycin when mixed for aerosol administration. Respir Care. 1991;36:1387–1390
  7. Nagtegaal JE, De Jong A, De Waard WJ, Van der Meer YG. Formulation and shelf life of two solutions for inhalation. Ziekenhuis farmacie. 1997;13:23–29
  8. Jacobson GA, Peterson GM. Stability of ipratropium bromide and salbutamol nebuliser admixtures. Int J Pharm Pract. 1995;3:169–173
  9. Hood JC, White TS. Stability of selected antibiotics solutions with albuterol and ipratropium inhalation solutions in the treatment of pulmonary infections. ASHP-Midyear-Clinical-Meeting 33 (1998) P-43E. Personal communication.
  10. Roberts GW, Badcock NR, Jarvinen AO. Cystic fibrosis inhalation therapy: stability of a combined salbutamol/colistin solution. Aust J Hosp Pharm. 1992;22:378–380
  11. Lesko LJ, Miller AK. Physical chemical compatibility of cromolyn sodium inhalation solution – bronchodilator inhalant solution admixtures. Ann Allergy. 1984;53:236–238
  12. Iacono M, Johnson GJ, Bury RW. An investigation of the compatibility of ipratropium and sodium cromoglycate nebuliser solutions. Aust J Hosp Pharm. 1987;17:158–161
  13. Turner M. Compatibility of nebuliser solutions (letter). Aust J Hosp Pharm. 1987;17:241–242
  14. Emm T, Metcalf JE, Lesko LJ, Chai MF. Update on the physical–chemical compatibility of cromolyn sodium inhalation solution: bronchodilator inhalant solution admixtures. Ann Allergy. 1991;66:185–189
  15. Smaldone GC, McKenzie J, Cruz Rivera M, Hoag J. Budesonide inhalation suspension is chemically compatible with other nebulizing formulations (Abstract). Chest. 2000;118:98
  16. McKenzie JE, Cruz Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother. 2004;38(6):967–972
  17. Grönberg S, Magnusson P, Bladh N. Chemical compatibility of budesonide inhalation suspension (Pulmicort™) with other nebulization products (Abstract). Meeting of the American Thoracic Society 2001. Personal communication.
  18. Tzung-Yiet L, Chi-Ming C, Chun-Nin L, Yi-Chun C, Hsiang-Yin C. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. Am J Health-Syst Pharm. 2005;62:828–833
  19. Rieutord A, Arnaud P, Dauphin JF, Brion F. Stability and compatibility of an aerosol mixture including N-acetylcysteine, netilmicin and betamethasone. Int J Pharm. 1999;190:103–107
  20. Joseph JC. Compatibility of inhalation solution admixtures. Ann Pharmacother. 1997;31:487–489
  21. Roberts GW, Rossi SOP. Compatibility of nebuliser solutions. Aust J Hosp Pharm. 1993;23:35–37
  22. Allen LV. Combination solutions for bronchospasm. US-Pharmacist. 1999;24:82–83
  23. Harriman AM, Purcell N, Fleming S, Daly MJ. Can we mix nebuliser solutions?. Pharm Pract. 1996;6:347–348
  24. Owsley HD, Rusho WJ. Compatibility of common respiratory therapy drug combinations. Int J Pharm Compd. 1997;1:121–122
  25. United States Pharmacopeial Convention, Inc. . The United States pharmacopeia. 24th Ed.. Rockville: United States Pharmacopeial Convention, Inc.; 2000;
  26. Pharmacopoeia European basic edition. 4th Ed. Deutscher Apotheker Verlag, Stuttgart, Govi-Verlag-Pharmazeutischer Verlag, Eschborn; 2002.
  27. Pharmacopoeia European 4th supplement. 4th Ed. Deutscher Apotheker Verlag, Stuttgart, Govi-Verlag-Pharmazeutischer Verlag, Eschborn; 2003
  28. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet. 1983;2:592–594
  29. McKenzie J, Gronberg S, Cruz M, Rivera J. Budesonide inhalation suspension can be nebulized with solutions containing albuterol sulphate (Poster). Chest. 2002;122:183S;[Suppl.]
  30. Smaldone GC, McKenzie J, Cruz Rivera M. Effect of nebulizer volume on drug delivery: budesonide inhalation suspension. Meeting of the American Thoracic Society, 2000. Personal communication.

PII: S1569-1993(06)00041-5

doi: 10.1016/j.jcf.2006.03.007

Journal of Cystic Fibrosis
Volume 5, Issue 4 , Pages 205-213 , December 2006

Article Tools